Sangamo and Novartis join forces to create gene therapies for autism and other brain disorders

Bay Area biotechnology company Sangamo Therapeutics has teamed up with multinational pharmaceutical giant Novartis International AG to take on autism spectrum disorder and other neurodevelopmental conditions. The collaboration, announced Thursday, will net Sangamo an upfront fee of $75 million with the potential to rake in $720 million, contingent on the Brisbane-base company’s ability to meet developmental and commercial milestones. It will also get a percentage— single-digit to sub-teens-digits—…

Click to view original post